Home ❯ Research projects ❯ IMMUTOL (Advanced antigen-specific dendritic cell-based therapy to re-establish tolerance in immunemediated diseases)

IMMUTOL (Advanced antigen-specific dendritic cell-based therapy to re-establish tolerance in immunemediated diseases)

Lead researcher

Jordi Martorell López, PhD

Research group

GEVAB – Vascular Engineering and Applied Biomedicine Group

Funds Source:

European Union

Period:

01/05/2023 to 30/04/2027

Project typology:

European consortium project

Project status:

ACTIVE

Funding Entity:

Comisión Europea (CE)

Funding:

273,779 €

IMMUTOL is the Accelerated development and validation of an advanced therapeutic drug (ATMP) based on modified VitD3

The aim of IMMUTOL isthe fast-track development and validation of an advanced therapeutic medicinal product (ATMP) based on VitD3-modified tolerogenic DC for immunotherapy approaches.

Through a multidisciplinary approach, IMMUTOL will leverage the power of tolerogenic VitD3DC-based immunotherapy to develop a more potent and durable treatment for MS and, in turn other autoimmune inflammatory diseases with an unmet medical need. In parallel, it will bring information about tolerance mechanisms and patient-specific requirements for manufacturing effective tolDC products.
https://immutol-horizon.eu

Research groups

GEVAB – Vascular Engineering and Applied Biomedicine Group

The GEVAB group develops its activity in two main areas: the development of biomaterials to treat vascular pathologies and the study of other clinical needs, integrating knowledge from medicine, biology, chemistry, physics, mathematics and computing.